ASX:MSBBiotechs
Why Mesoblast (ASX:MSB) Is Down 7.1% After Issuing First Detailed Ryoncil Revenue Guidance
Mesoblast Limited recently reported half-year 2025 results, with revenue rising to US$51.34 million and net loss and loss per share both narrowing, and subsequently issued fiscal 2026 guidance calling for US$110 million to US$120 million in Ryoncil net revenue.
This combination of sharply higher reported revenue and the first detailed full-year outlook for Ryoncil offers investors a clearer view of Mesoblast’s early commercial trajectory and cost profile.
We’ll now examine how Mesoblast’s...